SCHEMBL6091585

SCHEMBL6091585

COc1cccc(OC)c1C(=O)Cc1ccccc1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
TTR P02766 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.43
PPARA Q07869 1/20 0.43
CNR2 P34972 2/20 0.43
LY96 Q9Y6Y9 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091825 0.80 CNR2 (0.50) KMT2AMEN1CA12CA1CA2
SCHEMBL6092756 0.80 TTR (0.48) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL27598682 0.77 CA12 (0.58) KMT2AMEN1CA12CA1CA2
SCHEMBL27832518 0.76 CA9 (0.52) KMT2AMEN1CA12CA1CA2
SCHEMBL3459740 0.76 CA12 (0.52) KMT2AMEN1CA12CA1CA2
SCHEMBL755355 0.74 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL6091930 0.74 NPC1 (0.47) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL30676336 0.73 CA9 (0.57) KMT2AMEN1CA12CA1CA2
SCHEMBL965852 0.73 KMT2A (0.51) KMT2AMEN1CA12CA1CA2
SCHEMBL1717361 0.73 CA12 (0.74) KMT2AMEN1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ATHEROGENICS, INC. 2006-03-23 US disclosed
WO-2006004903-A2 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF ATHEROGENICS, INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ABCB11, CEL, CYP46A1 KMT2A 3991/4885MEN1 514/4885CA12 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.